NHU pharmaceutical raw materials
NHU is one of the national key high-tech enterprises, the company is mainly engaged in pharmaceuticals, health products, pharmaceutical raw materials, flavors and fragrances, food additives, feed additives and other series of more than 50 products production and sales. The main products of the company are vitamin E, vitamin A and ethoxymethane, which are mainly used in feed additives, health products and raw material medicine, NHU has passed the ISO9002 quality system certification (certification scope: production and service of rigid rotor vane pumps) by Wantai Certification.
Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
China, with a population of 1.4 billion, has one of the largest gene pools in the world. How does its DNA tech-based cancer detection industry look? Listed on Nasdaq in 2020, Genetron Holdings Limited (Genetron Health) is taking a leading role.
Sep 09, 2020 03:08 PM
ResearchHealthcare, Consumer Staples, Technology
WIA2020 | Rising Tech Stars 2020: Global & China's 100
ResearchConsumer Discretionary, Real Estate, Consumer Staples
Tech for Global, Globalization Footprints of the Established and the New
Sinopharm COVID Vaccine Receives WHO Emergency Use Certification
The Sinopharm Group’s COVID Vaccine is the sixth vaccine to receive safety, efficacy and quality verification from the World Health Organization (WHO). It is the first vaccine from a non-Western country to receive WHO certification.
May 11, 2021 03:35 AM
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM
Revenue and Net Profit of Wuxi Apptec Both Increased in 2020
Wuxi apptec said that the main reasons for the company's performance growth were the high growth of laboratories in China and the year-on-year growth of CDMO plate. China laboratory service is the core business of Wuxi apptec, accounting for more than 50% of its revenue. Its main business is small molecule drug discovery, drug analysis and testing.
Apr 01, 2021 04:39 PM